4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech ... in “early 2025” to launch a phase 1/2 study of the therapy, dubbed GLPG5201, in relapsed/refractory chronic ...

CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases.

Clinical trials with CART19 therapy have shown great efficacy in heavily pretreated patients with ... Recent clinical trials with new drugs, including bispecific antibodies, drug-conjugated antibodies ...

CD19 and BCMA CAR T-Cells is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Leukemia. According to GlobalData, Phase II drugs for Leukemia ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics, a leading cell and gene therapy statrtup backed by entrepreneur Kiran Mazumdar-Shaw, has unveiled Qartemi, the ...

If consummated, the deal will add a BCMA and CD19-targeted CAR-T therapy for blood cancers including ... CAR-Ts, and SMART CART technology for CAR-Ts that can target solid tumours.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...